{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', '13.5.7.', 'Health Outcome Analyses', 'Health Outcome endpoints are as follows:', 'EQ-5D-5L scores', 'TSQM scores', 'WPAI scores', 'The between-treatment comparisons for, EQ-5D-5L, TSQM, and WPAI will be performed using', 'a mixed-effect model, including terms of treatment, visit, treatment and visit interaction, and', 'baseline score. Details will be provided in the SAP.', '13.5.8.', 'Pharmacokinetic Analyses', 'Plasma samples for determination of BCX7353 concentrations are planned to be collected at', 'Baseline/Day 1, Weeks 4, 8, 12, 18, 24, 28, 32, 36, and 48 and early termination (if applicable).', 'The resulting PK data will be pooled in a meta-analysis to facilitate population PK analyses.', '13.5.9.', 'Pharmacodynamic Analyses', 'Plasma kallikrein inhibition data will be expressed as percent inhibition compared to subject', 'baseline activity. Ex vivo plasma kallikrein activity will be listed by subject, treatment, day, and', 'time and summarized separately by treatment, day, and time. Descriptive statistics will be', 'reported. Mean and individual plasma kallikrein inhibition VS. time profiles will be plotted by', 'treatment group.', '13.5.10. Pharmacokinetic/Pharmacodynamic Analyses', 'Exposure-response analyses of the relationships between plasma kallikrein inhibition, efficacy', 'endpoints, and BCX7353 plasma concentrations may be explored using model-based techniques', 'as applicable.', '14.', 'STUDY ADMINISTRATION', '14.1.', 'Regulatory and Ethical Considerations', '14.1.1.', 'Regulatory Authority Approvals', 'This study will be conducted in compliance with the protocol; Good Clinical Practices (GCPs),', 'including ICH of Technical Requirements for Registration of Pharmaceuticals for Human Use', 'Guidelines (ICH E6); FDA/European Medicines Agency regulatory requirements and other', 'national laws as applicable; and in accordance with the ethical principles of the Declaration of', 'Helsinki. In addition, the study will be conducted in compliance with all applicable local laws', 'and regulatory requirements relevant to the use of new therapeutic agents.', '14.1.2.', 'Institutional Review Board and Ethics Committee Approvals', 'Before initiation of the study at an investigational site, the protocol, the ICF, the subject', 'information sheet (if applicable), and any other relevant study documentation will be submitted', '98']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'to the appropriate IRB/IEC. Written approval of the study must be obtained before the study', 'center can be initiated or the IMP can be released to the Investigator. Any necessary extensions', 'or renewals of IRB/IEC approval must be obtained, in particular, for changes to the study, such', 'as modification of the protocol, the ICF, the written information provided to subjects, and/or', 'other procedures.', 'The IRB/IEC will be promptly provided any new information that may adversely affect the', 'safety of the subjects or the conduct of the study. On completion of the study, the IRB/IEC will', 'be provided with a report of the outcome of the study.', 'Written reports of clinical study status will be submitted to the IRB/IEC annually or more', 'frequently if requested by the IRB/IEC. A final study notification will also be forwarded to the', 'IRB/IEC after the study is completed or in the event of premature termination of the study in', 'accordance with the applicable regulations. The study will be considered completed once the last', 'subject completes the last study visit. Copies of all contact with the IRB/IEC should be', 'maintained in the study file. Copies of clinical study status reports (including termination) should', 'be provided to BioCryst.', '14.1.3.', 'Subject Informed Consent: Adults', 'A signed ICF must be obtained from each subject prior to performing any study-related', 'procedures. Each subject should be given both verbal and written information describing the', 'nature and duration of the clinical study. The informed consent process should take place under', 'conditions where the subject has adequate time to consider the risks and benefits associated with', 'his/her participation in the study. Subjects will not be screened or treated until the subject has', 'signed an approved ICF written in a language in which the subject is fluent.', 'The ICF that is used must be approved both by BioCryst and by the reviewing IRB/IEC. The ICF', 'should be in accordance with the current revision of the Declaration of Helsinki, current ICH and', 'GCP guidelines, and BioCryst policies.', 'The Investigator must explain to potential subjects the aims, methods, reasonably anticipated', 'benefits, and potential hazards of the trial and any discomfort it may entail. Subjects will be', 'informed that they are free not to participate in the trial and that they may withdraw consent to', 'participate at any time. They will be told that refusal to participate in the study will not prejudice', 'future treatment. They will also be told that their records may be examined by competent', 'authorities and authorized persons but that personal information will be treated as strictly', 'confidential and will not be publicly available. Subjects must be given the opportunity to ask', 'questions. After this explanation and before entry into the trial, consent should be appropriately', \"recorded by means of the subject's dated signature. The subject should receive a signed and\", 'dated copy of the ICF. The original signed ICF should be retained in the study files. The', 'Investigator shall maintain a log of all subjects who sign the ICF and indicate if the subject was', 'enrolled into the study or reason for nonenrollment.', '14.1.4.', 'Subject Informed Consent: Adolescents', 'Signed informed consent must be obtained from each parent/caregiver of adolescent subjects', 'aged 12 to 17 who enroll in the study prior to performing any study-related procedures.', 'Similarly, subject assent by subjects 12 to 17 years will be obtained from each adolescent prior', 'to performing any study-related procedures. If the local requirements limit the age of assent, then', '99']\n\n###\n\n", "completion": "END"}